{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:43:11Z","timestamp":1770756191486,"version":"3.50.0"},"reference-count":131,"publisher":"Georg Thieme Verlag KG","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470135"],"award-info":[{"award-number":["82470135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82001026"],"award-info":[{"award-number":["82001026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Project of China","award":["2023YFC2509500"],"award-info":[{"award-number":["2023YFC2509500"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:p>Platelets are among the most abundant cells in the body and play important roles in coagulation and immunity. Platelets are formed when hematopoietic stem cells proliferate and differentiate into megakaryocytes via the regulation of various cytokines. After the megakaryocytes mature in the bone marrow cavity, proplatelets are released into the blood circulation where they eventually remodel into mature platelets. Given that the production and functions of platelets involve the regulation of many factors\u2014such as hematopoietic stem cells, the hematopoietic microenvironment, and cytokines\u2014the causes and mechanisms of platelet-related diseases are diverse, often involving platelet production, clearance, and distribution. In this review, we examined the regulation of platelet production and summarized common disorders affecting platelet quantity, namely, thrombocytopenia and thrombocytosis. In addition, we reviewed previous clinical studies and summarized the medication strategies commonly used for the treatment of different platelet disorders in different clinical scenarios.<\/jats:p>","DOI":"10.1055\/a-2561-8818","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:51:07Z","timestamp":1742428267000},"source":"Crossref","is-referenced-by-count":4,"title":["Platelet Disorders and Medication Strategies"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2952-1789","authenticated-orcid":false,"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyuan","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/bloodadvances.2016000059","article-title":"Platelets and hemostasis: a new perspective on an old subject","volume":"1","author":"L F Brass","year":"2016","journal-title":"Blood Adv"},{"key":"ref2","first-page":"65","article-title":"Platelets: essential components of the immune system","volume":"16","author":"R A Ali","year":"2015","journal-title":"Curr Trends Immunol"},{"issue":"04","key":"ref3","first-page":"296","article-title":"[Management of thrombocytopenia]","volume":"39","author":"A Wolfromm","year":"2018","journal-title":"Rev Med Brux"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3324\/haematol.2010.035287","article-title":"Determinants of platelet count in humans","volume":"96","author":"M E Daly","year":"2011","journal-title":"Haematologica"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood-2018-11-835371","article-title":"Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation","volume":"133","author":"B Psaila","year":"2019","journal-title":"Blood"},{"issue":"7690","key":"ref6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature25455","article-title":"Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells","volume":"554","author":"J Carrelha","year":"2018","journal-title":"Nature"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCRESAHA.124.323579","article-title":"What it takes to be a platelet: evolving concepts in platelet production","volume":"135","author":"E Carminita","year":"2024","journal-title":"Circ Res"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2013-03-492330","article-title":"Biogenesis of the demarcation membrane system (DMS) in megakaryocytes","volume":"123","author":"A Eckly","year":"2014","journal-title":"Blood"},{"issue":"08","key":"ref9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s44161-023-00305-y","article-title":"Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36","volume":"2","author":"M N Barrachina","year":"2023","journal-title":"Nat Cardiovasc Res"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood.2023021292","article-title":"GPIb\u03b1-filamin A interaction regulates megakaryocyte localization and budding during platelet biogenesis","volume":"143","author":"M L Ellis","year":"2024","journal-title":"Blood"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.V60.1.213.213","article-title":"The demarcation membrane system of the megakaryocyte: a misnomer?","volume":"60","author":"J M Radley","year":"1982","journal-title":"Blood"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.2830100308","article-title":"Aspects of platelet formation and release","volume":"10","author":"G Scurfield","year":"1981","journal-title":"Am J Hematol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2014-09-600858","article-title":"Microtubule sliding drives proplatelet elongation and is dependent on cytoplasmic dynein","volume":"125","author":"M Bender","year":"2015","journal-title":"Blood"},{"issue":"03","key":"ref14","first-page":"915","article-title":"Dynamic actin\/septin network in megakaryocytes coordinates proplatelet elaboration","volume":"109","author":"I C Becker","year":"2024","journal-title":"Haematologica"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26508\/lsa.201800061","article-title":"Multiple membrane extrusion sites drive megakaryocyte migration into bone marrow blood vessels","volume":"1","author":"E Brown","year":"2018","journal-title":"Life Sci Alliance"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2005-06-2206","article-title":"Mechanisms of organelle transport and capture along proplatelets during platelet production","volume":"106","author":"J L Richardson","year":"2005","journal-title":"Blood"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2018-01-829259","article-title":"ADAP deficiency impairs megakaryocyte polarization with ectopic proplatelet release and causes microthrombocytopenia","volume":"132","author":"M Spindler","year":"2018","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"15838","DOI":"10.1038\/ncomms15838","article-title":"A Cdc42\/RhoA regulatory circuit downstream of glycoprotein Ib guides transendothelial platelet biogenesis","volume":"8","author":"S D\u00fctting","year":"2017","journal-title":"Nat Commun"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2019.239111","article-title":"Cytoskeletal-based mechanisms differently regulate in vivo and in vitro proplatelet formation","volume":"106","author":"A Bornert","year":"2021","journal-title":"Haematologica"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023020895","article-title":"The bone marrow is the primary site of thrombopoiesis","volume":"143","author":"N L Asquith","year":"2024","journal-title":"Blood"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1083\/jcb.201006102","article-title":"Cytoskeletal mechanics of proplatelet maturation and platelet release","volume":"191","author":"J N Thon","year":"2010","journal-title":"J Cell Biol"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1172\/JCI153920","article-title":"Sepsis promotes splenic production of a protective platelet pool with high CD40 ligand expression","volume":"132","author":"C Valet","year":"2022","journal-title":"J Clin Invest"},{"issue":"7648","key":"ref23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"E Lefran\u00e7ais","year":"2017","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.exphem.2018.04.001","article-title":"The physical and cellular conditions of the human pulmonary circulation enable thrombopoiesis","volume":"63","author":"Y Ouzegdouh","year":"2018","journal-title":"Exp Hematol"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"S Audia","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2014-03-563445","article-title":"Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia","volume":"124","author":"S Audia","year":"2014","journal-title":"Blood"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2008.03161.x","article-title":"Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura","volume":"7","author":"M Kuwana","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","article-title":"CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura","volume":"139","author":"S Li","year":"2007","journal-title":"Br J Haematol"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12026-014-8620-2","article-title":"Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients","volume":"61","author":"F Li","year":"2015","journal-title":"Immunol Res"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bjh.13292","article-title":"Interleukin 35 may contribute to the loss of immunological self-tolerance in patients with primary immune thrombocytopenia","volume":"169","author":"T Sun","year":"2015","journal-title":"Br J Haematol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"R Grozovsky","year":"2015","journal-title":"Nat Med"},{"issue":"14","key":"ref32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"A Cuker","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17474086.2023.2159803","article-title":"An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura","volume":"16","author":"I G\u00f3mez-Segu\u00ed","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"X L Zheng","year":"2015","journal-title":"Annu Rev Med"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MOH.0000000000000602","article-title":"Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management","volume":"27","author":"E Roose","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"J E Sadler","year":"2017","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"100945","DOI":"10.1016\/j.blre.2022.100945","article-title":"Advances in the management of TTP","volume":"55","author":"M Subhan","year":"2022","journal-title":"Blood Rev"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"H A van Dorland","year":"2019","journal-title":"Haematologica"},{"issue":"07","key":"ref39","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.151407","article-title":"Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers","volume":"103","author":"J Hrdinov\u00e1","year":"2018","journal-title":"Haematologica"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/jth.15170","article-title":"Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura","volume":"19","author":"L C Vel\u00e1squez Pereira","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2012-02-412197","article-title":"Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies","volume":"120","author":"T A Fuchs","year":"2012","journal-title":"Blood"},{"issue":"03","key":"ref42","first-page":"288","article-title":"Thrombocytopenia: evaluation and management","volume":"106","author":"R L Gauer","year":"2022","journal-title":"Am Fam Physician"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0039-1697930","article-title":"Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics","volume":"46","author":"E Danese","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"D Weycker","year":"2019","journal-title":"BMC Cancer"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.bmt.1700872","article-title":"Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation","volume":"20","author":"N S Trede","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"09","key":"ref46","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bcp.2007.06.047","article-title":"Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells","volume":"74","author":"J K Chang","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa065066","article-title":"Vancomycin-induced immune thrombocytopenia","volume":"356","author":"A Von Drygalski","year":"2007","journal-title":"N Engl J Med"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"M S Sulkowski","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"09","key":"ref49","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s12012-024-09895-w","article-title":"Association of metal cations with the anti-PF4\/heparin antibody response in heparin-induced thrombocytopenia","volume":"24","author":"J B Giles","year":"2024","journal-title":"Cardiovasc Toxicol"},{"issue":"22","key":"ref50","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"D Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"S Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ejim.2016.09.001","article-title":"Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia","volume":"37","author":"H Frederiksen","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"02","key":"ref53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"D Provan","year":"2010","journal-title":"Blood"},{"issue":"21","key":"ref54","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"B S Joly","year":"2017","journal-title":"Blood"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"C L Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"X G Liu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"08","key":"ref57","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","article-title":"The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials","volume":"21","author":"Y H Qin","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/08916934.2015.1104671","article-title":"Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases","volume":"49","author":"Z Zhou","year":"2016","journal-title":"Autoimmunity"},{"issue":"12","key":"ref59","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2217\/imt-2016-0088","article-title":"Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies","volume":"8","author":"L Kovaleva","year":"2016","journal-title":"Immunotherapy"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1179\/102453309X439773","article-title":"Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura","volume":"14","author":"T Robak","year":"2009","journal-title":"Hematology"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3324\/haematol.10667","article-title":"The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia","volume":"92","author":"R S Go","year":"2007","journal-title":"Haematologica"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study","volume":"12","author":"J Peng","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"J Gilreath","year":"2021","journal-title":"Drugs"},{"issue":"08","key":"ref64","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"N H Afdhal","year":"2012","journal-title":"N Engl J Med"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12185-017-2275-4","article-title":"Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice","volume":"106","author":"T J Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Int J Hematol"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"R Yang","year":"2017","journal-title":"Br J Haematol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12725","article-title":"Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice","volume":"97","author":"T J Gonz\u00e1lez-L\u00f3pez","year":"2016","journal-title":"Eur J Haematol"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","article-title":"Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies","volume":"31","author":"D D Williams","year":"2009","journal-title":"Clin Ther"},{"issue":"25","key":"ref69","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"J B Bussel","year":"2014","journal-title":"Blood"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"W Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpdd.349","article-title":"Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects","volume":"7","author":"M Nomoto","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2040620719841735","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"H Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"08","key":"ref73","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2016.161968","article-title":"Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia","volume":"102","author":"D B Cines","year":"2017","journal-title":"Haematologica"},{"issue":"04","key":"ref74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000381657","article-title":"Romiplostim treatment in adults with immune thrombocytopenia of varying duration and severity","volume":"134","author":"A Janssens","year":"2015","journal-title":"Acta Haematol"},{"key":"ref75","first-page":"99","article-title":"Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia","volume":"7","author":"P Vishnu","year":"2016","journal-title":"J Blood Med"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"S Chugh","year":"2015","journal-title":"Lancet Haematol"},{"issue":"22","key":"ref77","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"M Khellaf","year":"2014","journal-title":"Blood"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"D M Arnold","year":"2012","journal-title":"Blood"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11239-008-0208-z","article-title":"The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura","volume":"27","author":"S Pasa","year":"2009","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"E Lucchini","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"ref81","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5\u2009years from the French prospective registry ITP-ritux","volume":"94","author":"S Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"09","key":"ref82","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ajh.23272","article-title":"Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia","volume":"87","author":"F Zaja","year":"2012","journal-title":"Am J Hematol"},{"issue":"24","key":"ref83","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"E E Page","year":"2016","journal-title":"Blood"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange","volume":"40","author":"A Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"03","key":"ref85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study","volume":"43","author":"J Rubia","year":"2010","journal-title":"Transfus Apher Sci"},{"issue":"07","key":"ref86","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"J Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"05","key":"ref87","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"J B Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.12706","article-title":"Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"M Soucemarianadin","year":"2016","journal-title":"Eur J Haematol"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"82","author":"P Coppo","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"04","key":"ref90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"M Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref91","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"F Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"04","key":"ref92","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"L K\u00fchne","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref93","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2012.075648","article-title":"Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years","volume":"98","author":"N Vianelli","year":"2013","journal-title":"Haematologica"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.24341","article-title":"Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study","volume":"91","author":"F Zaja","year":"2016","journal-title":"Am J Hematol"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000442703","article-title":"Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study","volume":"135","author":"Y H Park","year":"2016","journal-title":"Acta Haematol"},{"issue":"48","key":"ref96","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"L H Thai","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.19077","article-title":"Is splenectomy a good strategy for refractory immune thrombocytopenia in adults?","volume":"203","author":"B Godeau","year":"2023","journal-title":"Br J Haematol"},{"issue":"01","key":"ref98","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08998280.2009.11928458","article-title":"Postsplenectomy reactive thrombocytosis","volume":"22","author":"P N Khan","year":"2009","journal-title":"Proc Bayl Univ Med Cent"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2019.02.010","article-title":"Reactive thrombocytosis in acute infectious diseases: prevalence, characteristics and timing","volume":"63","author":"A Schattner","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"03","key":"ref100","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"C N Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0002-9343(94)90306-9","article-title":"Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis","volume":"97","author":"A Tefferi","year":"1994","journal-title":"Am J Med"},{"issue":"04","key":"ref102","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"A Tefferi","year":"2024","journal-title":"Am J Hematol"},{"issue":"16","key":"ref103","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"A Tefferi","year":"2014","journal-title":"Blood"},{"issue":"01","key":"ref104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"A Tefferi","year":"2016","journal-title":"Am J Hematol"},{"issue":"04","key":"ref105","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","article-title":"Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature","volume":"5","author":"S Alimam","year":"2021","journal-title":"Blood Adv"},{"issue":"07","key":"ref106","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Y Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"08","key":"ref107","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.2022016846","article-title":"Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms","volume":"141","author":"C Pecquet","year":"2023","journal-title":"Blood"},{"issue":"12","key":"ref108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41408-018-0159-3","article-title":"MPL-mutated essential thrombocythemia: a morphologic reappraisal","volume":"8","author":"N Szuber","year":"2018","journal-title":"Blood Cancer J"},{"issue":"09","key":"ref109","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.6004\/jnccn.2022.7026","article-title":"Interferons as the first choice of cytoreduction in essential thrombocythemia and polycythemia vera","volume":"20","author":"J How","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"ref110","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"A Mullally","year":"2013","journal-title":"Blood"},{"issue":"32","key":"ref111","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref112","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"J J Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"06","key":"ref113","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera\u2014a systematic review and meta-analysis","volume":"35","author":"J P Bewersdorf","year":"2021","journal-title":"Leukemia"},{"issue":"03","key":"ref114","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12185-021-03171-1","article-title":"Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis","volume":"114","author":"W Gu","year":"2021","journal-title":"Int J Hematol"},{"issue":"07","key":"ref115","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"T A Knudsen","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"ref116","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"B Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"06","key":"ref117","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3324\/haematol.2022.281388","article-title":"Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?","volume":"108","author":"M Cattaneo","year":"2023","journal-title":"Haematologica"},{"issue":"08","key":"ref118","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"A Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"08","key":"ref119","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"1120911","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials","volume":"14","author":"B Noce","year":"2023","journal-title":"Front Pharmacol"},{"issue":"09","key":"ref121","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2012.157","article-title":"Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation","volume":"26","author":"A Spr\u00fcssel","year":"2012","journal-title":"Leukemia"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood-2022-159047","article-title":"A phase 2 study of the LSD1 inhibitor bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET)","volume":"140","author":"H Gill","year":"2022","journal-title":"Blood"},{"issue":"01","key":"ref123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jca.21847","article-title":"Therapeutic thrombocytapheresis in myeloproliferative neoplasms: a single-institution experience","volume":"36","author":"T H Nguyen","year":"2021","journal-title":"J Clin Apher"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/asheducation-2015.1.61","article-title":"Mechanical circulatory support: balancing bleeding and clotting in high-risk patients","volume":"2015","author":"L Baumann Kreuziger","year":"2015","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"05","key":"ref125","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1055\/s-0040-1709524","article-title":"Platelet activation via shear stress exposure induces a differing pattern of biomarkers of activation versus biochemical agonists","volume":"120","author":"Y Roka-Moiia","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jbiomech.2016.11.016","article-title":"Shear-mediated platelet activation in the free flow: perspectives on the emerging spectrum of cell mechanobiological mechanisms mediating cardiovascular implant thrombosis","volume":"50","author":"M J Slepian","year":"2017","journal-title":"J Biomech"},{"issue":"04","key":"ref127","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/ATVBAHA.120.315583","article-title":"Platelet dysfunction during mechanical circulatory support: elevated shear stress promotes downregulation of \u03b1IIb\u03b23 and GPIb via microparticle shedding decreasing platelet aggregability","volume":"41","author":"Y Roka-Moiia","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"18","key":"ref128","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood-2011-10-386607","article-title":"Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels","volume":"119","author":"M Al-Tamimi","year":"2012","journal-title":"Blood"},{"issue":"06","key":"ref129","doi-asserted-by":"crossref","first-page":"H2128","DOI":"10.1152\/ajpheart.00107.2009","article-title":"Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ibalpha shedding","volume":"297","author":"H Cheng","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"06","key":"ref130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/MAT.0000000000000722","article-title":"Quantitative characterization of shear-induced platelet receptor shedding: glycoprotein Ib\u03b1, glycoprotein VI, and glycoprotein IIb\/IIIa","volume":"64","author":"Z Chen","year":"2018","journal-title":"ASAIO J"},{"issue":"08","key":"ref131","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1055\/s-0035-1546296","article-title":"Bleeding and thrombotic events in patients undergoing mechanical circulatory support: a review of literature","volume":"63","author":"M Petricevic","year":"2015","journal-title":"Thorac Cardiovasc Surg"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2561-8818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T22:56:03Z","timestamp":1746658563000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2561-8818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":131,"URL":"https:\/\/doi.org\/10.1055\/a-2561-8818","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,19]]},"published":{"date-parts":[[2025,3,19]]}}}